Flagship Pioneering launched a new company called Inzen Therapeutics, which will discover and develop a new class of medicines based on a new area of biology that will provide new therapeutic approaches to multiple types of diseases.
Pfizer Takes Stake in Rhythm Pharmaceuticals
Appetite, Bardet-Biedl Syndrome (BBS), Bardet-Biedl Syndrome (BBS), Biological Pathways, Business, Diabetic Gastroparesis, Equity Stake, Genetic Disorders, Ghrelin Agonists, Melanocortin-4 Receptor (MC4R) Agonists, Monogenic Disorders, Obesity, Pro-Opiomelanocortin (POMC) Deficiency Obesity, Product Pipelines, Rare Diseases, Stock Markets, U.S. Securities and Exchange Commission (SEC)Pfizer snapped up a small percentage of Rhythm Pharmaceuticals, which is focused on treating rare genetic disorders that lead to obesity.
AbbVie has acquired an option on an early-stage immuno-oncology drug from biotech company Argenx, giving the U.S. drugmaker access to a treatment with the potential to block a biological pathway that allows cancers to grow. Dutch-Belgian Argenx will receive $40 million upfront from AbbVie for the exclusive option to license ARGX-115 and near-term preclinical milestones […]